Tedopi®
Non-Small Cell Lung Cancer (NSCLC) after checkpoint inhibitor failure
Phase 3Active (ARTEMIA trial)
Key Facts
Indication
Non-Small Cell Lung Cancer (NSCLC) after checkpoint inhibitor failure
Phase
Phase 3
Status
Active (ARTEMIA trial)
Company
About OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on controlling the immune system for therapeutic benefit in cancer and inflammatory diseases. The company's strategy is built on three proprietary research platforms that generate novel candidates in immuno-oncology and immuno-inflammation. Its most advanced program, Tedopi®, has received positive recommendations from an independent data monitoring committee in its pivotal Phase 3 ARTEMIA trial. OSE aims to accelerate development through strategic partnerships with premier international pharmaceutical, clinical, and academic collaborators.
View full company profile